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Neurodegenerative diseases are characterized by the progressive loss of specific neurons in selected 
regions of the Central Nervous System. The main clinical manifestation (movement disorders, 
cognitive impairment, and/or psychiatric disturbances) depends on the neuron population being 
primarily affected. Parkinson’s disease is a common movement disorder, whose aetiology remains 
mostly unknown. Progressive loss of dopaminergic neurons in the substantia nigra causes an 
impairment of the motor control. Some of the pathogenetic mechanisms causing the progressive 
deterioration of these neurons are not specific for Parkinson’s Disease but are shared by other 
neurodegenerative diseases, like Alzheimer Disease and Amyotrophic Lateral Sclerosis. 
Here, we performed a meta-analysis of the literature of all the quantitative proteomic 
investigations of neuronal alterations in different models of Parkinson’s Disease, Alzheimer Disease 
and Amyotrophic Lateral Sclerosis, to distinguish between general and Parkinson’s Disease specific 
pattern of neurodegeneration. Then, we merged proteomics data with genetics information from the 
DisGeNET database. The comparison of genes and proteins information allowed us to identify 25 
proteins involved uniquely in Parkinson’s Disease and we verified the alteration of one of them, i.e., 
Transaldolase 1 (TALDO1), in the substantia nigra of 5 patients. By using open-source 
bioinformatics tools, we identified the biological processes specifically affected in Parkinson’s 
Disease, i.e., proteolysis, mitochondrion organization, mitophagy. Eventually, we highlighted four 
cellular component complexes mostly involved in the pathogenesis: the proteasome complex, the 
protein phosphatase 2A, the chaperonins CCT complex and the complex III of the respiratory chain. 
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Neurodegenerative disorders are characterized by the progressive deterioration of neuronal 
systems in the central nervous system (CNS). The loss of neurons results in movement disorders, 
cognitive impairment, and/or psychiatric disturbances. The pathological defects that underlie 
neurodegenerative disorders are fairly well defined and usually involve the progressive death of 
specific neurons in selected regions of the CNS. Despite of their distinct aetiologies, 
neurodegenerative disorders probably share pathogenetic mechanisms that involve oxidative stress, 
unfolded protein response and mitochondrial impairment [1]. Although the main clinical 
manifestations of each disorder depend on the neuron population being primarily affected, some 
individuals show signs and symptoms indicating the extension of the pathology to other systems [2-
4]. 
Parkinson’s Disease (PD) is a multifactorial neurodegenerative disorder, whose aetiology 
remains largely unknown. Early in the course of the disease, the symptoms are movement-related, 
including tremor, rigidity, slowness of movement and difficulty with walking and gait [5,6]. 
Progressive impairment of motor control is caused by the specific loss of dopaminergic neurons in 
the substantia nigra (SN) and the formation of intra-neuronal proteinaceous inclusions, called Lewy 
bodies (LBs) [7,8]. The progressive deterioration of vulnerable SN dopaminergic neurons may arise 
from cellular disturbances caused by misfolding and aggregation of the synaptic protein alpha 
synuclein [9], the disruption of the autophagy-lysosome system [10], mitochondrial dysfunction 
[11], endoplasmic reticulum (ER) stress [12], and dysregulation of calcium homeostasis [13]. These 
pathways are not specific for PD but they are shared by Alzheimer Disease (AD) [14] and 
Amyotrophic Lateral Sclerosis (ALS) [2] and there is recent evidence supporting the view that ALS 
and PD share common pathogenetic mechanisms. Indeed, the frequency of extrapyramidal 
symptoms in ALS patients is significantly higher than in the general population [15,16].  
Current research on the molecular bases of neurodegenerative disorders using omics 
technologies (e.g., genomics, proteomics, and metabolomics) have enabled high-throughput 
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monitoring of a variety of molecular and organismal processes. These techniques have been 
generally applied to identify biological variants, to characterize the involved complex biochemical 
systems and to study pathophysiological processes. While many omics platforms target 
comprehensive analysis of genes (genomics), mRNA (transcriptomics), proteins (proteomics), and 
metabolites (metabolomics) [17], challenges remain for omics-domain data integration [18]. 
Changes in mRNA levels do not always correlate with similar changes in protein levels or activity, 
therefore studies evaluating protein expression changes in neurodegenerative models are crucial 
[19]. The most common methods of proteome analysis are the comparative two-dimensional 
electrophoresis (2-DE), followed by mass spectrometry (MS), and shotgun proteomics, based on a 
gel-free approach. 2-DE shows a better workbench for the characterization of post-translational 
modifications. However, shotgun proteomics provides a better sensitivity and resolution [20]. 
In the present study we analyzed the biological processes that result to be altered in PD, 
making a comparison with two other neurodegenerative disorders; AD, as the most studied 
neurodegenerative condition, and ALS, as a movement disorder affecting the motor neurons, 
instead of a midbrain neuron population as in PD. To this end, we performed a meta-analysis of the 
literature encompassing all the proteomic investigations published so far concerning neuronal 
alterations in PD, ALS and AD. Unlike the meta-analysis of clinical studies, we collected all data 
on proteins that have been reported to be quantitatively altered in either diseases. We then combined 
these data with disease-linked genes taken from curated disease-gene databases (DisGeNET) [21] in 
order to unveil disease-specific biological pathways. This allowed us to obtain an enriched dataset 




Materials and methods 
Input lists generation 
A meta-analysis of the literature was obtained by gathering all proteomic investigations of 
neuronal alterations in PD, ALS and AD. The search was conducted in PubMed database, using the 
following search terms: “proteom*[Title/Abstract]) AND Parkinson* [Title/Abstract]”. All English 
language studies found in the database and published within the end of 2015 were considered. Only 
full text original articles focused on the development of the disease in the CNS were included. 
Therefore, all papers on peripheral biomarkers and on the drug influence on the pathogenesis were 
manually filtered out. All protein IDs were converted to the corresponding human Uniprot ID. 
Genetic information taken from the curated database DisGeNET (http://disgenet.org, v4 released 
April 15th 2016) were also collected. The following search terms were used in DisGeNET: PD 
(umls:C0030567), ALS (umls:C0002736) and AD (umls:C0002395). 
 
Bioinformatics analysis 
By merging the protein input lists for the three diseases, proteins were divided between 
disease-specific (only-PD_Proteins, only-ALS_Proteins and only-AD_proteins) and in common 
among different disease states. In order to identify genes and proteins specific for PD (PD_Proteins-
Genes), the tool InteractiVenn was used (http://www.interactivenn.net/) [22].   
The over-representation analysis (ORA) was carried out using the GO Consortium 
(http://geneontology.org/ ) and Reactome (http://www.reactome.org/ ) databases. Only significant 
pathways (p-value < 0.05) were taken in account. In order to compare the results obtained after the 
analysis of the input lists, we used GOView (http://www.webgestalt.org/GOView/ ). GOView is a 
web-based application which allows both visualization and comparison of multiple GO term lists in 
a directed acyclic graph (DAG) able to unveil relationships among terms.  
Networks were built using the web portal BioProfiling (http://www.bioprofiling.de ). This 
tool includes almost all the available information concerning signalling and metabolic pathways 
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(databases: Reactome and KEGG) and physical protein-protein interaction (PPI) (database: IntAct) 
[23]. Accordingly, the protein input list was analysed with the PPI spider [24] tool. The p-value 
provided, computed by Monte Carlo simulation, refers to the probability to get a model of the same 
quality starting from a random gene list of the same size [23]. The significant D1 networks (all 
nodes belong to the input list, p < 0.01) were considered to further interpret and discuss proteomics 
results. The networks were exported as .xgmml files and edited using Cytoscape 3.2.0 
(http://www.cytoscape.org/) [25]. 
To perform network topology analysis of the enriched networks, we used the 
NetworkAnalyzer Cytoscape application. NetworkAnalyzer performs analysis of biological 
networks providing network topology parameters including the diameter of a network, the average 
number of neighbours and the number of connected pairs of nodes. Distributions of more complex 
network parameters such as node degrees, average clustering coefficients, topological coefficients 
and shortest path lengths were also computed [26]. Again, the GO Consortium was used to perform 
ORA (GO terms). 
 
Western blot analysis of SN samples 
Mesencephalic tissues from five sporadic PD patients and five controls (defined by the Brain 
Bank as non-demented, since they did not show any sign of dementia at the time of death) 
(Supplementary Table 1) were obtained from the Netherlands Brain Bank (NBB), Netherlands 
Institute for Neuroscience, Amsterdam. All material has been collected from donors for or from 
whom a written informed consent for a brain autopsy and the use of the material and clinical 
information for research purposes had been obtained by the NBB.  
The tissue specimens (approximately 12 mg) were put in a Potter homogenizer together with 
500 μl of tissue lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton, 2 mM 
ethylenediaminetetraacetic acid (EDTA) 1 mM 1,4-dithiothreitol (DTT), 1x phosphatase inhibitors 
(Roche), 1× phenylmethylsulfonyl fluoride (PMSF), 1× protease inhibitor cocktails (PIC) and then 
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manually lysed. After this procedure, the samples were incubated on ice for 30 minutes and then 
sonicated (0.5 cycles, 15 pulses, twice). Then, the lysates were centrifuged at 18000×g for 15 
minutes at 4°C.  
Total protein concentration was quantified using the bicinchoninic acid (BCA) method (Pierce). 
Equal amounts of proteins were resolved in 10% sodium dodecyl sulfate (SDS,TGX Stain-Free 
FastCast Acrylamide Kit, 10%, BioRad) and the fluorescent stain activated by UV light, following 
manufacturer’s instructions. Then, proteins were transferred to polyvinylidene difluoride (PVDF) 
membranes at 1.0 mA/cm2 for 2 hours (TE77pwr; Hoefer) and the fluorescent signal acquired 
(GelDoc-Ite Imaging System; UVP). Membranes were saturated for 2 hours at room temperature in 
tris-buffered saline tween (TBST), integrated with 5% of skimmed milk powder and then incubated 
with anti-TALDO1 (Abcam ab67467,1:500) and β-actin (GeneTex GTX23280, 1:8000) primary 
antibody overnight at 4°C, in 5% milk-TBST. Incubation with anti-mouse (Millipore 12-349, 
1:1500) peroxidase-conjugated secondary antibody in 5% milk-TBST was then performed. 
Enhanced chemiluminescence substrate (Millipore Corporation) was used in order to visualize the 
peroxidase signals: images (16 bit grayscale) were finally acquired using the G:BOXChemi XT4 
(Syngene) system and analyzed using the ImageJ software [27] (https://imagej.nih.gov/ij/), 





Assembly of gene and protein lists 
In order to gather valuable information for the assembly of the input lists, a meta-analysis of 
the literature was performed, including all the proteomic investigations of AD, PD and ALS disease 
models. Full-texts of the selected articles were used to extract information about proteins altered by 
the three diseases and to generate the input lists (Table 1). We identified 762, 420 and 139 papers in 
PubMed about proteomic investigations in AD, PD and ALS, respectively. The studies retained 
(healthy/disease comparison and quantitative proteomic studies) were 40 for AD, 46 for PD and 
only 9 for ALS (Supplementary Table 2). We generated three input lists: AD_Proteins (928 
proteins), PD_Proteins (1155 proteins) and ALS_Proteins (387 proteins) (Table 1). 
 
Table 1. Principal steps of the meta-analysis procedure and number of IDs in each input list. 
 Pubmed hits  
Healthy/disease comparisons 
and quantitative proteomic 
studies
_Proteins _Genes 
AD 762 40 928 1663 
PD 420 46 1155 766 
ALS 139 9 387 799 
 
We analyzed the three lists in order to identify proteins that were not unique to a specific 
disease (Fig. 1). On the other hand, we observed that 675 proteins resulted to be altered in PD only 
(only-PD_Proteins input list). As far as the intersections are concerned, PD and ALS shared 69 
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Table 2. Summary table of the most significant results of the GO Biological Processes analysis of 
“_Proteins” input lists, after GoView filtering. 
AD_Proteins PD_Proteins ALS_Proteins 
Apoptotic process 
Electron transport chain 
Axon guidance 
Intracellular protein transport 
Protein targeting 
Signaling pathway (Fc receptor, NIK/NF-kappaB) 
 
Cell cycle phase 
Establishment of protein localization to endoplasmic reticulum  
DNA damage response 
Nuclear-transcribed mRNA catabolic process, nonsense-
mediated decay 
Negative regulation of neuron apoptotic process 
Establishment of synaptic vesicle localization 
Mitochondrial membrane organization  
Mitochondrial transport 
Signaling pathway (ERBB, Fc epsilon, fibroblast growth factor 
receptor, insulin receptor, epidermal growth factor receptor) 
 
G2/M transition of mitotic cell 
cycle  
G2/M transition of mitotic cell 
cycle 




Proteolysis involved in cellular 
protein catabolic process 
Mitochondrion localization 
Mitophagy 
Signaling pathway (ephrin 
receptor, tumor necrosis factor, 
canonical Wnt)  
rRNA metabolic process 
ncRNA metabolic process  






Table 3. Summary table of the most significant results of the GO Biological Processes analysis of 
“_Genes” input lists, after GoView filtering. 
AD_Genes PD_Genes ALS_Genes 
Regulation of cellular catabolic process 
Regulation of peptidyl-serine phosphorylation 
Regulation of protein transport 
Regulation of apoptotic signaling pathway 
 
Regulation of myelination 
Positive regulation of nuclear division 
Cellular response to xenobiotic stimulus  
Regulation of mitochondrial membrane permeability 
Calcium ion transport 
Signaling pathway (ERBB, Fc receptor) 
 




Cellular response to glucose 
stimulus  










Cellular response to glucose 
stimulus  





Positive regulation of glycolytic 
process 
Icosanoid biosynthetic process  
Regulation of fatty acid 
biosynthetic process 
Positive regulation of cholesterol 
transport 
Signaling pathway (Notch, Wnt, 
Toll-Like Receptors, tumor 
necrosis factor) 
Dopamine biosynthetic and 
catabolic process 
Response to oxygen radical 
Apoptotic mitochondrial 
changes 
Cellular iron ion homeostasis 
RNA transport 
Nuclear import 







The “Apoptotic process” served as an internal control, since alterations in the apoptotic 
pathway resulted to be present in all of the three diseases (PD, AD and ALS). Similarly, the ORA 
analysis unveiled the alteration of protein transport as a common feature of the three diseases 
(“Protein targeting” and “Regulation of protein transport”). On the other hand, the ORA allowed us 
to identify disease-specific pathways. Indeed, in PD we recognized a central role for mitochondria 
both in “_Proteins” (“Mitophagy” and “Mitochondria localization”) and in “_Genes” analyses 
(“Apoptotic mitochondria change”). Furthermore, alterations in proteasomal function (“Proteolysis 
involved in cellular protein catabolic process”) and “Response to oxygen radical” were observed. 
By contrast, cytoskeleton organization, ion homeostasis and lipid biosynthetic process resulted to be 
altered in AD, while aberrant RNA processing appeared to be mainly involved in ALS pathogenesis 
(“rRNA metabolic process”, “ncRNA metabolic process”, “mRNA splicing, via splicesome”). 
In order to identify which pathways are over-represented when only PD-specific proteins are 
considered, an ORA of only-PD_Proteins input list (675 IDs) was performed. To this purpose, we 
used GO Consortium Biological Process and Reactome as reference databases. Again, we found 
“Mitophagy” and apoptotic process (“Regulation of apoptosis”), but we also found out 




Table 4. Summary table of the most significant results of the GO Biological Processes and 
Reactome analysis of only PD_Proteins input list. 
Only-PD_Proteins (675 IDs) 
Go Consortium Biological Process Reactome  
Vesicle-mediated transport 
Regulation of apoptotic process 
Regulation of cell motility 
Protein complex assembly 
Signaling pathway (MAPK cascade, insulin 
receptor signaling pathway, epidermal growth 
factor receptor signaling pathway, vascular 
endothelial growth factor receptor signaling 
pathway, neurotrophin TRK receptor signaling 
pathway, fibroblast growth factor receptor 
signaling pathway, NIK/NF-kappaB signaling, 
Wnt signaling pathway, planar cell polarity 
pathway) 
Regulation of protein catabolic process 
Actin cytoskeleton organization 
Modulation of synaptic transmission 
Mitochondrion organization 
Translation 
Nuclear-transcribed mRNA catabolic process, 
nonsense-mediated decay 
SRP-dependent cotranslational protein targeting 
to membrane 
Cellular response to heat stress  
DNA replication 
Laminin interactions 
Nonsense-Mediated Decay (NMD) 
Mitophagy (PINK1/Parkin mediated 
Mitophagy) 
Metabolism of aminoacid and derivates 
Translation 
Regulation of apoptosis 
Signaling pathway (signaling by EGFR, 
signaling by FGFR, signaling by NGF, 
signaling by PDGF, signaling by VEGF, MAPK 
family signaling cascade, signaling by Wnt, 
signaling by Hedgehog) 
Membrane trafficking 
 
Strikingly, the latter pathways are overrepresented in the PD_Proteins-Genes analysis, too 
(Supplementary Table 4). 
 
Physical interactions network 
Starting from the protein input lists previously generated, one for each disease considered 
("_Proteins"), we decided to perform a network-based analysis, using the IntAct database as a 
reference set. With this approach, we generated a direct interactor network (D1 network) for each 
disease (Supplementary Fig. 1) and we then merged them (Supplementary Fig. 2). In this way, we 
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Neurodegenerative diseases are multifactorial in nature involving several genetic mutations 
(in coding or regulatory regions), epigenetic and environmental factors, the greatest risk factor 
being age [32]. Multifactorial diseases can be investigated using a global approach at the systems 
level [33]. Proteomics offers a global snapshot at the molecular level of proteins and consequently 
processes that regulate neuronal death. The integration of this view with genetic information can 
help to understand general mechanisms of neurodegeneration. To the purpose of finding molecular 
pathways specifically involved in PD, we used AD as a control, to eliminate pathway generically 
linked to neurodegeneration. Moreover, we included ALS in the analysis, being another disorder of 
motor control, although affecting a distinct neuronal population (i.e., motor neurons). The aetiology 
of AD, PD and ALS remains largely unknown. Therefore, we performed a meta-analysis of the 
literature and merged the results of only those papers containing proteomics experiments about 
neuronal modifications in PD, ALS and AD, including papers on human tissues, animal models and 
cellular models, and excluding works about pharmacological effects of particular molecules or 
peripheral biomarkers.  
The meta-analysis approach presented here may have some limits. First, we decided to 
include only quantitative proteomics studies. We tried to overcome this issue using data coming 
from a genetic database (DisGeNET) and taking into account only the “consensus” pathways 
obtained by the ORA of both proteins and genes lists, in this way overcoming also the issue of false 
results present in the literature. Another weakness of retrieving data from the literature is the few 
proteomics information about ALS compared to those of PD and AD. Consequently, the molecular 
picture obtained for ALS was less complete than the one for the other two diseases. Eventually, the 
ORA of long lists of proteins/genes generates huge lists of pathways where it is difficult to select 
those biologically relevant. Having access to primary quantitative data should be a method to filter 
out some less relevant results, using tools such as the Gene Set Enrichment Analysis (GSEA).  
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There is an extensive evidence that demonstrates the close relationship between ALS and 
PD at the clinical [34;35], genetic [15], neuroimaging [36] and pathological level in humans 
[37,38], as well as at the pathological level in preclinical models [39]. In addition, mutations in 
several ALS-related genes, e.g., ANG and FUS [40-44], could provide a genetic link between ALS 
and frontotemporal dementia (FTD). Furthermore, C9orf72, TARDBP, and VCP can constitute a 
common genetic background among ALS and FTD, and, to a lesser extent, PD [42,45,46]. The 
analysis of the three “_Proteins” lists displayed a major overlap between PD and ALS compared to 
that of AD and ALS. Thus, the two motor disorders may share also common pathways of 
neurodegeneration, even though occurring in different cell types.   
In order to identify PD-specific proteins, we eliminated all the proteins shared by AD and 
ALS and thus generated an only-PD_Proteins input list. Of these proteins, 25 were also found in the 
DisGeNET database. Probably they constitute major molecular hallmarks of PD, since they were 
never found to be altered in the other two pathologies and were reported both at the proteomic and 
the genetic levels. Many of them are ribosomal proteins, thus being implicated in protein synthesis. 
Another category over-represented in this group is the cellular response to stress. Eventually, 
TALDO1 was identified. Our group have already identified TALDO1 in T-lymphocytes, as part of 
a protein signature able to discriminate PD patients from control subjects and patients affected by 
atypical parkinsonism [47]. Therefore, this protein may mirror at the peripheral level an alteration 
occurring in the CNS [48]. Moreover, since this evidence was only based on one paper in the 
literature [48], we verified the up-regulation of the protein in 5 SN specimens of PD patients, with 
respect to 5 control subjects. As a proof-of-principle of our bioinformatics analysis, the increased 
level of the protein was confirmed in our samples. Although it is difficult to speculate about the link 
between a single protein and a complex, multifactorial disease, we may envisage a role of the 
pentose phosphate pathway in the regulation of mitochondrial homeostasis in the presence of 
enhanced oxidative stress [49]. Indeed, aberrant control of mitochondrial function has been reported 
in a cellular model that specifically recapitulates dopamine-linked oxidative stress [11]. 
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Moving from protein identities to pathway analysis, we performed an ORA on the “_Genes” 
and “_Proteins” input lists, using the GO consortium, to highlight disease-specific processes. We 
expected that pathways shared by all three diseases were general hallmarks of cell death. Indeed, 
the ORA underlined the over-representation of the apoptotic process, which we used as a kind of 
positive control. Moreover, the ORA stressed the involvement of the Electron Transport Chain 
(ETC) in all three diseases. The respiratory chain, especially in pathological conditions, can be a 
source of reactive oxygen species (ROS). Markers of oxidative stress and ROS damage are elevated 
in PD, AD and ALS. A high level of ROS causes a damage to various cellular components and 
ultimately results in the activation of apoptosis [3]. Regarding the ALS specific-pathways, the 
involvement of RNA processing was particularly evident: metabolism (“rRNA metabolic process”, 
“ncRNA metabolic process”), transport (“Nuclear transport”, “Nuclear import” and “RNA 
transport”) and splicing (“mRNA splicing”) were all over-represented ontologies. Although 
Mitochondrial membrane organization and mitochondrial transport are involved in AD and PD, 
notably “Mitophagy” is over-represented only in PD. Alteration of the mitochondrial quality control 
and the consequent mitochondrial impairment have been widely associated to apoptosis directly 
triggered by these organelles (“Apoptotic mitochondrial changes”) [50]. The ORA of the only-
PD_Proteins input list (i.e., proteins involved in PD never related to ALS and AD) again 
highlighted the importance of “Mitophagy”. This list gave us the opportunity to focus on proteins 
never associated to AD and ALS. At the same time, important pathways may be neglected due to 
the exclusion of too many members of the ontology under consideration. Keeping in mind 
advantages and shortcomings of this sub-list, we decided to perform the ORA using also a database 
of metabolic pathways, to evidence possible specific mechanisms. Some signal transduction 
cascades were suggested by the analysis. As an example, the Wnt signalling pathway emerged as a 
pathway commonly dysregulated in PD [51].  
Eventually, we focused on protein complexes involved specifically in PD. The analysis of 
the PD interactor network evidenced four protein complexes: the proteasome 26S, the ETC complex 
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III, the CCT complex and the PPP2A complex. Focusing on these complexes, we decided to 
retrieve quantitative information from original papers. Since it was impossible to compare papers 
using different scales and normalization methods, we decided to categorize variations as up- or 
down-regulations. In the proteasome complex, it was possible to identify a different action of the 
PD pathogenetic process on the expression of members of the catalytic subunit (proteasome 20S) 
and of the 26S protease regulatory subunit. The formers were all up-regulated, whereas the latter 
were all down-regulated. PD has been considered for long time a proteasome disease [52] and our 
analysis seems to confirm this hypothesis. In the ETC complex III, proteins were reported to be 
regulated in different directions by the original papers, probably because of the use of different 
models [53]. This may indicate different alterations in the respiratory chain due to different 
perturbations. The involvement of the ETC dysfunction in PD has always been related to complex I 
[54] and the inhibition of this complex by MPTP is used to reproduce parkinsonism in animal 
models [55]. Nevertheless, considering all the results together allowed us to highlight also the role 
of complex III. The CCT complex has been demonstrated to play an active role in the protection of 
dopaminergic neurons [56], being composed by chaperonins. All the proteins of the CCT complex 
were reported as down-regulated in the papers considered in the present analysis, probably 
indicating an overwhelming of their re-folding/protective capacities. PPP2A is a protein complex 
composed by structural (A), regulatory/targeting (B) and catalytic (C) subunits. Some of these 
subunits are direct interactors of CCT complex chaperonins [57] and are implicated in many PD-
related pathways. Indeed, this phosphatase controls Akt phosphorylation and thus macroautophagy 
[58], the activity of tyrosine hydroxylase (i.e., dopamine synthesis rate-limiting enzyme) [59] and 
alpha-synuclein aggregation [60].  
To sum up, this analysis highlighted processes generically involved in neuronal death and 
pathways related to the loss of specific neuronal populations in the different diseases. In particular, 
it clarified cellular pathways specifically involved in PD. Moreover, the analysis highlighted the 
fundamental role played by four protein complexes in leading neurodegeneration in PD. This may 
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be useful for future research to better understand disease-specific mechanisms and general 
alterations related to neurodegeneration.  
24 
 
Conflict of interest 










s” list (c), u
-based anal
sing the In
ysis of the 
tAct databa
“AD_Prote




























 of AD, PD
se-specific
 and ALS P










Supplementary Table 1. Characteristics of PD patients and gender and age related control subjects 
(CTRL).  
NBB number Sex Age Diagnosis 
2007-013 M 61 PD 
2009-003 M 62 CTRL 
2007-029 M 67 PD 
1999-116 M 78 CTRL 
2006-062 M 87 PD 
2009-001 M 88 CTRL 
2009-045 F 59 PD 
2001-004 F 64 CTRL 
2009-078 F 88 PD 
1999-111 F 88 CTRL 
Notes: NBB: Netherlands Brain Bank; M: Male, F: Female; CTRL: control subjects, PD: 
Parkinson’s disease 
Supplementary Table 2. PMIDs of studies used to generate _Proteins lists.  
 PMID 
AD 
11747211, 15756939, 15797529, 16519965, 17050040, 17111439, 17309106, 
18648492, 18648646, 19241155, 20061648, 21237293, 21368863, 21388376, 
21699958, 21883897, 21954051, 22559202, 22634250, 22926577, 23050487, 
23154051, 23211594, 23231993, 23276639, 23391701, 23424162, 23457027, 
23512986, 23537733, 23963966, 24306222, 24606058, 24893329, 25108202, 
25457556, 25756589, 25818006, 25958317, 26059363 
PD 
15526345, 15755676, 15790536, 16150055, 16565515, 16889417, 17203978, 
17490626, 17532186, 17705834, 18173235, 18226537, 18270577, 18338827, 
18353766, 18384645, 18782562, 19498008, 19725078, 20155936, 20334438, 
20403401, 20563739, 20594931, 20977677, 21136655, 21296869, 21322648, 
21960009, 21988495, 22315971, 22410244, 22445325, 23562983, 24040246, 
24449343, 24675778, 24737941, 24806433, 24834013, 24834013, 24841483, 
25626353, 25683516, 25865804, 26468903 
ALS 17979159, 17196550, 16847061, 15863242, 15501831, 19357085, 12475980, 25743254 
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Supplementary Table 3. Summary table of the most significant results of the GO Biological 
Processes and Reactome analysis of PD_Proteins-Genes input list. 
PD_Proteins-Genes (25 IDs): 
Go Consortium Biological Process Reactome 
Alpha-amino acid metabolic process  
Cellular amino acid metabolic process  
Selenocysteine metabolic process  
Small molecule metabolic process  
Cellular response to heat stress  
Metabolism of aminoacid and derivates 
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Supplementary Table 4. Summary of the protein level variations in PD complexes. ↓ indicates a 
down-regulation of the protein in PD, ↑ indicates up-regulation of proteins in PD. 
Gene Symbol Expression Pubmed ID Model used 
Respiratory 
chain 
UQCRB ↓ 24449343 Human SN 
UQCRC1 
↓ 24841483 Striatum in unilateral 6-OHDA-rat model 
↑ 22445325 α-synuclein overexpression in SH-SY5Y cells 
UQCRC2 
↓ 22410244 Human SN 
↓ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (1 day) 
↑ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (7 days) 
UQCRH 
↑ 21960009 Nigrostriatal area in A53T and wt α-synuclein mice 
↓ 15790536 SN in mice treated chronically with MPTP for 5 weeks 
UQCRSF1 
↑ 20403401 SN in 6-OHDA rat model 
↓ 18270577 Striatum in MPTP macaque model  
↑ 16565515 Human SN 
CYC1 
↑ 18173235 Striatum in MPTP and METH mice models 




↑ 16150055 Cortical and striatal tissue of PARK2 knockout mice 
↑ 25865804 mutant parkin (Q311R and A371T) overexpression in SH-SY5Y cells 
CCT4 
↑ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (1 day) 
↑ 18173235 Striatum in MPTP mice model 
↑ 18173235 Striatum in METH mice model 
CCT5 
↓ 22445325 α-synuclein overexpression in SH-SY5Y cells 
↑ 21322648 MPTP-treated N2a cells 
↓ 15790536 SN in mice treated chronically with MPTP for 5 weeks 
↑ 25626353 Whole brain in PINK1 knockout mice 
CCT6A ↑ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (1 day) 
CCT7 
↑ 22445325 α-synuclein overexpression in SH-SY5Y cells 
↑ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (1 day) 
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 Gene Symbol Expression Pubmed ID Model used 
PPP2A 
complex 
PPP2CA ↓ 24449343 Human SN 
PPP2CB 
↑ 16150055 Cortical and striatal tissue in PARK2 knockout mice 
↑ 26468903 α-synuclein fibrils-exposed SH-SY5Y cells  
PPP2R4 ↓ 20403401 SN in 6-OHDA rat model ↑ 20403401 SN in 6-OHDA rat model 
PPP2R5A ↓ 15790536 SN in mice treated chronically with MPTP for 5 weeks 
Proteasome 
complex 
PSMB1 ↑ 21296869 Parkin-expressing SH-SY5Y cells treated with CCCP 
PSMB3 ↑ 21296869 Parkin-expressing SH-SY5Y cells treated with CCCP 
PSMB5 
↑ 21296869 Parkin-expressing SH-SY5Y cells treated with CCCP 
↑ 16150055 Cortical and striatal tissue in PARK2 knockout mice 
PSMA1 
↑ 22315971 Co-expression of wt or mutated LRRK2 and Tau in C. elegans 
↑ 21296869 Parkin-expressing SH-SY5Y cells treated with CCCP 
PSMA3 
↑ 21960009 Nigrostriatal area in A53T and wt α-synuclein mice 
↑ 21296869 Parkin-expressing SH-SY5Ycells  treated with CCCP 
PSMA7, 
PSMA5 
↑ 21296869 Parkin-expressing SH-SY5Ycells  treated with CCCP 
↓ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (1 day) 
PSMC2 
↓ 20403401 SN in 6-OHDA rat model 
↓ 22445325 α-synuclein overexpression in SH-SY5Y cells 
PSMC1 ↓ 15790536 SN in mice treated chronically with MPTP for 5 weeks 
PSMC3 ↓ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (1 day) 
UCHL5 ↓ 17705834  Rotenone-treated MES cells  
USP14 ↑ 18173235 Striatum in MPTP and METH mice models 
6-OHDA: 6-hydroxydopamine, LRRK2: Leucine-rich repeat kinase 2, MES cells: dopaminergic 
neuronal cell line, METH: methamphetamine, MPTP:1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine, N2a cells: murine neuroblastoma cell line, PARK2: Parkin gene, PINK1: 
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